Literature DB >> 21063479

Clinical utility of prothrombin induced by vitamin K absence in the detection of hepatocellular carcinoma in Indian population.

Balkrishan Sharma, Radhika Srinivasan, Yogesh Kumar Chawla, Shweta Kapil, Nitin Saini, Bhupesh Singla, Anuradha Chakraborthy, Naveen Kalra, Ajay Duseja, Radha Krishan Dhiman.   

Abstract

BACKGROUND: Alpha-fetoprotein (AFP) is a well known widely used biomarker for the detection of hepatocellular carcinoma (HCC); however, it suffers from a low sensitivity and specificity. Protein or prothrombin induced by vitamin K absence or antagonist II (PIVKA-II) is another tumor marker elevated in HCC but not extensively used. AIM: Evaluation of PIVKA-II and AFP in diagnosing HCC in India. PATIENTS AND METHODS: The study group consisted of 70 consecutive HCC patients, 38 patients with cirrhosis, 30 patients with chronic hepatitis, and 30 normal healthy subjects. All patients were evaluated for PIVKA-II and AFP levels by ELISA. RESULT: The mean plasma concentration of PIVKA-II in HCC, cirrhotic, chronic hepatitis patients and healthy controls was 101.07 ± 78.30 ng/ml, 2.45 ± 4.25 ng/ml, 1.50 ± 0.98 ng/ml and 0.79 ± 0.75 ng/ml, respectively. Receiver operating characteristic (ROC) curve was plotted for PIVKA-II and AFP. At a cutoff level of 9.2 ng/ml for PIVKA-II a sensitivity of 80% and a specificity of 92.1% was found, whereas AFP at a cutoff level of 13.02 ng/ml showed 72.9% sensitivity and 65.8% specificity. No significant relationship of plasma levels of PIVKA-II was observed in HCC with HBsAg/antiHCV positivity and associated portal vein thrombosis, but a positive correlation was seen with the tumor size (P = 0.001). However, no such significant association was found with AFP.
CONCLUSION: PIVKA-II was more sensitive and specific than AFP for diagnosing HCC in the Indian population.

Entities:  

Keywords:  Alpha-fetoprotein; Area under curve; Hepatocellular carcinoma; Protein induced by vitamin K absence or antagonist II; Receiver operating characteristic curve

Year:  2010        PMID: 21063479      PMCID: PMC2940002          DOI: 10.1007/s12072-010-9186-2

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  41 in total

1.  Estimating the world cancer burden: Globocan 2000.

Authors:  D M Parkin; F Bray; J Ferlay; P Pisani
Journal:  Int J Cancer       Date:  2001-10-15       Impact factor: 7.396

2.  The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin.

Authors:  G L Grazi; A Mazziotti; C Legnani; E Jovine; R Miniero; A Gallucci; G Palareti; G Gozzetti
Journal:  Liver Transpl Surg       Date:  1995-07

3.  Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients.

Authors:  Y Koike; Y Shiratori; S Sato; S Obi; T Teratani; M Imamura; H Yoshida; S Shiina; M Omata
Journal:  Cancer       Date:  2001-02-01       Impact factor: 6.860

4.  Plasma des-gamma-carboxyprothrombin in the early stage of hepatocellular carcinoma.

Authors:  S L Tsai; G T Huang; P M Yang; J C Sheu; J L Sung; D S Chen
Journal:  Hepatology       Date:  1990-03       Impact factor: 17.425

Review 5.  Hepatocellular carcinoma: epidemiology, risk factors, and screening.

Authors:  Morris Sherman
Journal:  Semin Liver Dis       Date:  2005       Impact factor: 6.115

6.  Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group.

Authors:  M Ishii; H Gama; N Chida; Y Ueno; H Shinzawa; T Takagi; T Toyota; T Takahashi; R Kasukawa
Journal:  Am J Gastroenterol       Date:  2000-04       Impact factor: 10.864

7.  Serum glutamic oxalacetic transaminase/glutamic pyruvic transaminase ratios in hepatocellular carcinoma.

Authors:  Y Shimokawa; K Okuda; Y Kubo; A Kaneko; T Arishima; E Nagata; M Hashimoto; Y Sawa; Y Nagasaki; M Kojiro; K Sakamoto; T Nakashima
Journal:  Cancer       Date:  1977-07       Impact factor: 6.860

8.  Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma.

Authors:  Richard K Sterling; Lennox Jeffers; Fredric Gordon; Alan P Venook; K Rajender Reddy; Shinji Satomura; Futoshi Kanke; Myron E Schwartz; Morris Sherman
Journal:  Clin Gastroenterol Hepatol       Date:  2008-09-17       Impact factor: 11.382

9.  Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma.

Authors:  Ke-Qin Hu; Namgyal L Kyulo; Nelson Lim; Brijie Elhazin; Donald J Hillebrand; Tracy Bock
Journal:  Am J Gastroenterol       Date:  2004-05       Impact factor: 10.864

10.  AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease.

Authors:  Gary Beale; Dipankar Chattopadhyay; Joe Gray; Stephen Stewart; Mark Hudson; Christopher Day; Paolo Trerotoli; Gianluigi Giannelli; Derek Manas; Helen Reeves
Journal:  BMC Cancer       Date:  2008-07-18       Impact factor: 4.430

View more
  10 in total

1.  Serum levels of angiogenic and anti-angiogenic factors: their prognostic relevance in locally advanced hepatocellular carcinoma.

Authors:  Bal Krishan Sharma; Radhika Srinivasan; Shweta Kapil; Bhupesh Singla; Nitin Saini; Yogesh Kumar Chawla; Anuradha Chakraborti; Ajay Duseja; Naveen Kalra; Radha Krishan Dhiman
Journal:  Mol Cell Biochem       Date:  2013-08-04       Impact factor: 3.396

2.  Clinical utility of protein induced by vitamin K absence in patients with chronic hepatitis B virus infection.

Authors:  Bui Xuan Truong; Yoshihiko Yano; Vu Tuong VAN; Yasushi Seo; Nguyen Hoai Nam; Nguyen Khanh Trach; Takako Utsumi; Takeshi Azuma; Yoshitake Hayashi
Journal:  Biomed Rep       Date:  2012-08-24

3.  Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease.

Authors:  Agostino Colli; Tin Nadarevic; Damir Miletic; Vanja Giljaca; Mirella Fraquelli; Davor Štimac; Giovanni Casazza
Journal:  Cochrane Database Syst Rev       Date:  2021-04-15

4.  Efficacy of PIVKA-II in prediction and early detection of hepatocellular carcinoma: a nested case-control study in Chinese patients.

Authors:  Rentao Yu; Xiaomei Xiang; Zhaoxia Tan; Yi Zhou; Haoliang Wang; Guohong Deng
Journal:  Sci Rep       Date:  2016-10-12       Impact factor: 4.379

5.  Combining des-gamma-carboxyprothrombin and alpha-fetoprotein for hepatocellular carcinoma diagnosing: an update meta-analysis and validation study.

Authors:  Huaping Chen; Siyuan Chen; Shan Li; Zhijian Chen; Xuan Zhu; Meiyu Dai; Lingxi Kong; Xiaodan Lv; Zhili Huang; Xue Qin
Journal:  Oncotarget       Date:  2017-08-07

6.  The threshold of alpha-fetoprotein (AFP) for the diagnosis of hepatocellular carcinoma: A systematic review and meta-analysis.

Authors:  Jiaxin Zhang; Guang Chen; Peng Zhang; Jiaying Zhang; Xiaoke Li; Da'nan Gan; Xu Cao; Mei Han; Hongbo Du; Yong'an Ye
Journal:  PLoS One       Date:  2020-02-13       Impact factor: 3.240

7.  Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization.

Authors:  Yong Kang Lee; Seung Up Kim; Do Young Kim; Sang Hoon Ahn; Kwang Hun Lee; Do Yun Lee; Kwang-Hyub Han; Chae Yoon Chon; Jun Yong Park
Journal:  BMC Cancer       Date:  2013-01-03       Impact factor: 4.430

8.  Alpha-fetoprotein and novel tumor biomarkers as predictors of hepatocellular carcinoma recurrence after surgery: a brilliant star raises again.

Authors:  Quirino Lai; Fabio Melandro; Rafael S Pinheiro; Andrea Donfrancesco; Bashir A Fadel; Giovanni B Levi Sandri; Massimo Rossi; Pasquale B Berloco; Fabrizio M Frattaroli
Journal:  Int J Hepatol       Date:  2012-06-27

9.  Performance of Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) for Hepatocellular Carcinoma Screening in Chinese Population.

Authors:  Rentao Yu; Shitao Ding; Wenting Tan; Shun Tan; Zhaoxia Tan; Shiqing Xiang; Yi Zhou; Qing Mao; Guohong Deng
Journal:  Hepat Mon       Date:  2015-07-22       Impact factor: 0.660

Review 10.  A Systematic Review of Des-γ-Carboxy Prothrombin for the Diagnosis of Primary Hepatocellular Carcinoma.

Authors:  Ji De; Yi Shen; Jinyu Qin; Li Feng; Yiping Wang; Li Yang
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.